Fig 1: ELISA replication of candidate DEPs in MoMar plasma. Box plots show concentrations of B2M (ng/mL), TF (µg/mL), and C4 (µg/mL) in pre-diagnostic cases versus asbestos-exposed non-cancer controls. No significant differences were observed for any marker
Fig 2: ELISA validation of candidate DEPs in pre-diagnostic EPIC sera. Box plots display serum concentrations of B2M (ng/mL), C4 (µg/mL), TF (µg/mL), and DCD (µg/mL) in cases sampled 0–2 years and 2–5 years before PM diagnosis versus matched controls. B2M showed a borderline significant increase in the 0–2 year group (t-test and GLM p < 0.05); TF, C4, and DCD trended similarly but were not significant. Asterisks indicate nominal p < 0.05
Fig 3: Receiver operating characteristics (ROC) analysis of combined biomarker panels in pre-diagnostic PM cases. (A) EPIC cohort: ROC curves for models using B2M alone (mod1, AUC = 0.71), B2M + C4 + TF (mod2, AUC = 0.81), Mesothelin + Calretinin (mod3, AUC = 0.65), and all five markers (mod4, AUC = 0.88; p-value = 0.17 vs. mod1 by DeLong’s test). (B) MoMar cohort: ROC curves for the same models (mod1 AUC = 0.55), mod2 (AUC = 0.75), mod3 (AUC = 0.84), and mod4 (AUC = 0.91; p = 0.001 vs. mod1)
Supplier Page from Abcam for Human Beta-2-Microglobulin ELISA Kit